Securities Lawsuit Alert: Beta Bionics, Inc. (BBNX) – Contact Levi & Korsinsky Before November 3, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding the seriousness of an FDA Form 483 and concealed thousands of safety complaints, including life-threatening events. Investors who suffered losses are encouraged to contact Levi & Korsinsky before November 3, 2026, to learn about their rights.
Securities Class Action Lawsuit Filed Against Beta Bionics, Inc. (BBNX) - Levi & Korsinsky Represents Shareholders
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made false and misleading statements regarding a Form 483, downplaying the seriousness of safety complaints and misrepresenting the scope of issues identified by the FDA. Investors who suffered losses are encouraged to contact Levi & Korsinsky to learn about potential recovery options.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
Levi & Korsinsky, LLP reminds Beta Bionics, Inc. shareholders of a lead plaintiff deadline of November 3, 2026, in a securities class action lawsuit. The lawsuit alleges that the company made false or misleading statements regarding the safety and regulatory standing of its iLet Bionic Pancreas, leading to a significant stock price decline. Shareholders who purchased shares between July 30, 2025, and February 24, 2026, may be eligible to recover losses due to the alleged operational impact and uninvestigated complaints.
Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
ClaimsFiler is alerting investors of Beta Bionics (BBNX) about a lead plaintiff deadline of November 3, 2026, in a securities class action lawsuit. The lawsuit alleges that Beta Bionics failed to disclose critical information regarding its iLet Bionic Pancreas insulin pump, including malfunctions, numerous uninvestigated customer complaints, and issues with FDA reporting and quality management. Investors who purchased BBNX stock between July 30, 2025, and February 24, 2026, and incurred losses exceeding $100,000 are encouraged to contact ClaimsFiler for legal options.
BBNX Shareholder Alert: Beta Bionics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
SueWallSt has announced a class action lawsuit against Beta Bionics, Inc. (BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false or misleading statements regarding the iLet insulin pump, particularly by failing to disclose over 18,000 customer complaints and a subsequent FDA Warning Letter. Investors have until November 3, 2026, to apply for lead plaintiff appointment.
Beta Bionics, Inc. (BBNX) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Beta Bionics, Inc. (BBNX) stock, including its current price, historical data, and key financial statistics. It details the company's focus on medical devices for insulin-requiring diabetics, its flagship iLet Bionic Pancreas, and its development pipeline. The page also offers performance metrics compared to the S&P 500, earnings trends, analyst insights, and valuation measures.
Lost Money on Beta Bionics, Inc. (BBNX)? Contact Levi & Korsinsky to Join Class Action Before November 3, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered losses. The lawsuit alleges that the company made false and misleading statements and concealed critical information regarding FDA observations and numerous safety complaints about its iLet device. Investors who purchased BBNX securities between July 30, 2025, and February 24, 2026, are encouraged to contact the firm to explore their rights.
Lost Money on Beta Bionics, Inc. (BBNX)? Join Class Action Before November 3, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made false and misleading statements regarding FDA observations and the seriousness of thousands of safety complaints, including life-threatening events, related to its iLet product. Investors who suffered losses are encouraged to contact the firm by November 3, 2026, to explore their rights.
Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) and its officers, alleging violations of federal securities laws. The lawsuit claims that the company made false and misleading statements regarding the FDA's observations concerning its iLet Bionic Pancreas insulin pump, including unreported serious injuries and deficiencies in its quality management system. Investors who purchased Beta Bionics securities between July 30, 2025, and February 24, 2026, are encouraged to join the case and may seek to be appointed as lead plaintiff by November 3, 2026.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX
Levi & Korsinsky, LLP is reminding shareholders of Beta Bionics, Inc. (BBNX) that a lead plaintiff deadline of November 3, 2026, has been set for a securities class action lawsuit. The lawsuit alleges that Beta Bionics abandoned a safety net for its iLet dosing algorithm and failed to investigate over 18,000 customer complaints, leading to a 72% drop in stock value. Shareholders who acquired shares between July 30, 2025, and February 24, 2026, may qualify for recovery.
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, downplaying FDA concerns about manufacturing and product issues. Investors have until November 3, 2026, to seek appointment as lead plaintiff in the case.
Levi & Korsinsky Notifies Beta Bionics, Inc. (BBNX) Investors - Lead Plaintiff Deadline on November 3, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) on behalf of investors who acquired securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made false and misleading statements regarding a Form 483 relating to thousands of safety complaints, including life-threatening hypoglycemic events, which were downplayed or not reported to the FDA. Investors who suffered losses are encouraged to contact Levi & Korsinsky by the lead plaintiff deadline of November 3, 2026.
Robbins LLP Urges BBNX Stockholders to Contact the Firm for Information About the Class Action Against Beta Bionics, Inc.
Robbins LLP is urging Beta Bionics, Inc. stockholders to contact the firm regarding a class action lawsuit filed against the company. The lawsuit alleges that Beta Bionics misled investors about the safety and efficacy of its iLet Bionic Pancreas insulin pump, which caused significant losses for investors. The firm is seeking lead plaintiffs for the lawsuit before the November 3, 2026 deadline.
Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance -- HBSS
Beta Bionics (NASDAQ: BBNX) is facing a securities fraud class action lawsuit after its stock price significantly dropped due to revelations about FDA concerns regarding its iLet automated insulin delivery system. The lawsuit alleges that Beta Bionics concealed thousands of iLet safety complaints, including life-threatening hypoglycemic events, and failed to investigate or report these incidents to the FDA as required. Hagens Berman is investigating the claims and encouraging investors who suffered substantial losses to come forward.
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Beta Bionics (BBNX) recently announced a partnership with Senseonics (SENS) to integrate its iLet Bionic Pancreas with Senseonics’ Eversense 365 continuous glucose monitoring system, aiming to broaden device choice for diabetes patients and strengthen its market position. Despite the long-term potential benefits of expanded CGM compatibility and a growing diabetes management market, BBNX shares fell over 8% following the announcement and are down significantly year-to-date. The integration, along with the future mint system, is expected to launch commercially in Q4 2026.
A 4:30 p.m. ET call will review Beta Bionics' third-quarter performance on Oct. 27.
Beta Bionics (BBNX) announced it will release its third-quarter 2026 financial results after markets close on October 27, 2026. Management will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the company’s performance. The webcast link and replay will be available on the company’s investor relations website.
Securities Fraud Class Action Filed Against Beta Bionics, Inc. (BBNX) - Levi & Korsinsky Reminds Investors of November 3, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that defendants made false and misleading statements and concealed critical information regarding the seriousness of FDA observations and thousands of safety complaints related to their iLet product. Investors are reminded of the November 3, 2026, deadline to explore potential recovery.
BBNX Investor Lawsuit: Beta Bionics Sued for Securities
A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ:BBNX) and its executives for securities fraud. The lawsuit alleges that Beta Bionics misled investors regarding the safety, efficacy, and commercial success of its iLet medical device, leading to significant stock drops. Investors have until November 3, 2026, to apply to be appointed lead plaintiff in the case.
Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholde
The Rosen Law Firm has announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics misled investors regarding its iLet Bionic Pancreas insulin pump, which reportedly malfunctioned, causing dangerously high insulin doses and life-threatening hypoglycemic events. Shareholders are encouraged to contact the firm to learn about their rights, with a lead plaintiff motion deadline set for November 3, 2026.
Beta Bionics, Inc. (BBNX) stock price, news, quote and history
This page provides a comprehensive overview of Beta Bionics, Inc. (BBNX) stock, including its current price, historical data, key financial statistics, and recent news. The company, a medical device firm, specializes in solutions for insulin-requiring individuals with diabetes, offering products like the iLet Bionic Pancreas. The data also includes analyst ratings and performance against benchmarks like the S&P 500.
November 3, 2026 Deadline: Join Class Action Lawsuit Against Beta Bionics, Inc. (BBNX) – Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) for investors who suffered losses between July 30, 2025, and February 24, 2026. The lawsuit alleges that the company made false and misleading statements regarding a Form 483 report, downplaying the seriousness of safety complaints and the scope of FDA observations. Investors have until November 3, 2026, to join the class action.
Faruqi & Faruqi, LLP Urges Beta Bionics (BBNX) Investors to Seek Counsel Before November 3, 2026 Lead Plaintiff Deadline in the Securities Class Action
Faruqi & Faruqi, LLP has announced a securities class action against Beta Bionics (NASDAQ: BBNX), urging investors who purchased stock between July 30, 2025, and February 24, 2026, to seek counsel before the November 3, 2026 lead plaintiff deadline. The lawsuit alleges that Beta Bionics made misleading statements regarding its iLet Bionic Pancreas insulin pump, concealing serious FDA findings related to the device's quality management and unreported injuries. Investors are encouraged to contact the law firm to discuss their legal options, as the company's shares fell approximately 37% after alleged corrective disclosures.
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
Rosen Law Firm is encouraging investors of Beta Bionics, Inc. (NASDAQ: BBNX) who purchased common stock between July 30, 2025, and February 24, 2026, to secure legal counsel before the November 3, 2026 lead plaintiff deadline. A class action lawsuit has been filed, alleging that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump, which reportedly malfunctioned and caused dangerously high insulin levels in patients. The firm emphasizes its track record in securities class actions and urges investors to act to potentially recover damages.
Kaplan Fox & Kilsheimer LLP Encourages Beta Bionics, Inc. (NASDAQ: BBNX) Investors to Contact the Firm Before November 3, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges Beta Bionics failed to disclose serious issues with its iLet Bionic Pancreas insulin pump, including malfunctions causing life-threatening hypoglycemia. Investors are encouraged to contact the firm before November 3, 2026, to potentially serve as a lead plaintiff.
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has notified investors in Beta Bionics, Inc. (NasdaqGM: BBNX) of a class action securities lawsuit. The lawsuit alleges that Beta Bionics made false or misleading statements regarding its iLet Bionic Pancreas insulin pump, which is accused of malfunctioning and causing hypoglycemic events due to an aggressive dosing algorithm. Investors who purchased Beta Bionics common stock between July 30, 2025, and February 24, 2026, have until November 3, 2026, to request to be appointed as lead plaintiff.
Class Action Lawsuit Filed: Beta Bionics, Inc. (BBNX) - Join by November 3, 2026 - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who suffered losses due to alleged securities fraud between July 30, 2025, and February 24, 2026. The lawsuit claims that Beta Bionics made false and misleading statements regarding the seriousness of an FDA Form 483 and failed to disclose thousands of safety complaints related to its iLet device. Investors are invited to join the lawsuit by November 3, 2026, to explore potential recovery.
Beta Bionics (BBNX) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline
A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics misled investors regarding FDA concerns about its iLet automated insulin delivery system and concealed thousands of safety complaints, including life-threatening events. Hagens Berman is investigating these claims and encourages affected investors to come forward before the November 3, 2026 lead plaintiff deadline.
Beta Bionics, Inc. (BBNX) Receives a Buy from Truist Financial
Truist Financial analyst Richard Newitter has assigned a Buy rating to Beta Bionics, Inc. (BBNX) with a $28.00 price target, following a similar Buy rating from Wells Fargo. Despite positive analyst ratings, corporate insider sentiment for BBNX is negative, with recent insider selling of shares. The company reported $32.01 million in quarterly revenue and a GAAP net loss of $23.4 million for the quarter ending June 30.
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
Schall, Brown & Schwartz LLP has filed a federal securities class action lawsuit against Beta Bionics, Inc. on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, particularly concerning FDA observations and the severity of unreported device malfunctions. Investors have until November 3, 2026, to seek appointment as lead plaintiff in the case.
Lost Money on Beta Bionics, Inc. (BBNX)? Contact Levi & Korsinsky Before November 3, 2026 to Join Class Action
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ:BBNX) on behalf of investors who suffered losses due to alleged securities fraud between July 30, 2025, and February 24, 2026. The lawsuit claims that the company made false and misleading statements regarding FDA Form 483 observations, downplaying the seriousness of safety complaints and failing to disclose numerous life-threatening events. Investors are encouraged to contact Levi & Korsinsky before November 3, 2026, to learn about their rights to potentially recover losses.
BBNX Investors: Beta Bionics, Inc. Shares Declined By
Kirby McInerney LLP is investigating a securities fraud class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased securities between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made misleading statements and failed to disclose critical issues with its iLet Bionic Pancreas insulin pump, including malfunctions, dangerously high insulin dosing, and FDA warnings. The stock experienced significant drops following revelations about unexpected earnings misses, an FDA warning letter, and public disclosure of the FDA's concerns.
Beta Bionics Shareholder Alert: ClaimsFiler Reminds
ClaimsFiler is alerting investors of Beta Bionics, Inc. (BBNX) who suffered losses exceeding $100,000 that they have until November 3, 2026, to file lead plaintiff applications in a class action lawsuit. The lawsuit alleges that Beta Bionics and its executives failed to disclose critical information regarding the iLet Bionic Pancreas insulin pump, including malfunctions, unreported customer complaints, and issues identified by the FDA. The company is accused of violating federal securities laws through materially misleading statements.
Truist Raises Price Target on Beta Bionics to $28 From $23, Keeps Buy Rating
Truist has increased its price target for Beta Bionics (BBNX) to $28 from $23, while maintaining a "Buy" rating on the stock. Despite the raised target, Beta Bionics currently holds an average rating of overweight and a mean price target of $23.28 according to available data. The full MT Newswires article is a premium content piece requiring a subscription to access.
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025, and February 24, 2026, of the November 3, 2026 lead plaintiff deadline in a securities fraud lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, which purportedly had serious malfunctioning issues and caused dangerously high insulin levels in patients. Investors are encouraged to join the class action to seek compensation.
BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX). The lawsuit alleges that Beta Bionics concealed critical information, including an FDA Form 483 from June 2025 and over 18,000 unreported iLet complaints, leading to a significant drop in BBNX's stock price. Shareholders who purchased securities between July 30, 2025, and February 24, 2026, are encouraged to contact the firm to determine their eligibility for recovery and to seek lead plaintiff status by November 3, 2026.
Beta Bionics, Inc. (BBNX) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Beta Bionics, Inc. (BBNX) stock, including its current price, historical performance, key statistics, and analyst ratings. The company, a commercial-stage medical device firm, specializes in solutions for insulin-requiring individuals with diabetes, such as the iLet Bionic Pancreas. The page details financial highlights, recent news, and collaborations, giving investors a broad snapshot of BBNX's market position and future outlook.
A year-long glucose monitor is expected to join an automated insulin system in Q4
Beta Bionics (BBNX) has announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ Eversense 365 continuous glucose monitoring system. The commercial launch of the integrated iLet and Eversense 365 is targeted for Q4 2026, aiming to offer users a broader choice of CGM manufacturer options. This collaboration seeks to combine adaptive insulin dosing with year-long glucose sensing for people with diabetes.
Beta Bionics, Inc. Notice of November 3, 2026 Application
Kahn Swick & Foti, LLC (KSF) has filed a class action lawsuit against Beta Bionics, Inc. (NasdaqGM: BBNX) on behalf of investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics failed to disclose critical issues regarding its iLet Bionic Pancreas insulin pump, including aggressive dosing, device malfunctions causing hypoglycemic events, and thousands of unreported customer complaints, despite an FDA Form 483 and subsequent warning letter. Investors have until November 3, 2026, to request to be appointed as lead plaintiff.
Beta Bionics (NASDAQ: BBNX) director lines up $197K stock sale
Beta Bionics director Christina Jones has filed a Rule 144 notice to sell up to 8,942 shares of common stock, valued at approximately $197,081.68, through Morgan Stanley Smith Barney LLC on NASDAQ. These shares are derived from stock option exercises and restricted stock units. This planned sale follows a previous sale of 1,406 shares by Jones under a 10b5-1 plan in June 2026.
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX
The Rosen Law Firm is encouraging investors of Beta Bionics, Inc. (NASDAQ: BBNX) who purchased common stock between July 30, 2025, and February 24, 2026, to secure legal counsel before the November 3, 2026, lead plaintiff deadline for a securities class action. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, which reportedly malfunctioned and caused dangerously high insulin levels in patients. Investors are advised to visit the firm's website or contact them directly to join the class action.
Kaplan Fox Urges Beta Bionics, Inc. (NASDAQ: BBNX) Investors to Contact the Firm Before the Deadline on November 3, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics concealed serious malfunctions and an aggressive dosing algorithm in its iLet Bionic Pancreas insulin pump, leading to patient complaints and an FDA warning letter. Investors are urged to contact Kaplan Fox before the November 3, 2026, deadline to potentially serve as a lead plaintiff.
Beta Bionics Announces Partnership to Integrate iLet and mint AID Systems with Senseonics’ Eversense 365 CGM
Beta Bionics has partnered with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system. This integration aims to provide users with more choices for diabetes management, with a commercial launch expected in Q4 2026. The collaboration highlights a shared commitment to innovation in diabetes care and expands Beta Bionics' reach to a larger group of people with diabetes.
BBNX Class Action: Beta Bionics Investors are Notified of the Upcoming November 3 Deadline in Ongoing Securities Fraud Class Action over Medical Device Safety
Bleichmar Fonti & Auld LLP has filed a securities fraud class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) after its stock fell over 37% due to alleged misrepresentation regarding the safety and efficacy of its iLet medical device. Investors are encouraged to seek additional information, with a lead plaintiff deadline of November 3, 2026. The lawsuit claims Beta Bionics concealed over 18,000 unreported complaints, including instances of life-threatening hypoglycemia, and that the company's stock dropped significantly after these issues and missed patient start estimates were revealed.
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Beta Bionics, Inc. (NasdaqGM:BBNX) on behalf of investors who purchased common stock between July 30, 2025, and February 24, 2026. The lawsuit alleges that Beta Bionics made false and misleading statements regarding its iLet Bionic Pancreas insulin pump, which is accused of delivering dangerously high insulin levels and causing hypoglycemic events. Investors have until November 3, 2026, to apply to be a lead plaintiff in the case.
BBNX LAWSUIT: Beta Bionics, Inc. Sued For Securities Fraud; Inves
Block & Leviton LLP has filed a securities fraud lawsuit against Beta Bionics, Inc. (Nasdaq: BBNX) and its executives. The lawsuit alleges that the company misled investors about the safety of its iLet Bionic Pancreas automated insulin pump, despite receiving numerous customer complaints, including life-threatening incidents. Investors who purchased BBNX common stock between July 30, 2025, and February 24, 2026, and incurred losses, are encouraged to contact Block & Leviton by November 3, 2026, to learn about their legal rights.
Germantown's Senseonics Partners with Beta Bionics to Pair Its Year-Long CGM with an Automated Insulin Pump
Senseonics Holdings, Inc., a Germantown-based glucose monitoring company, has partnered with Beta Bionics, Inc. to integrate its Eversense 365 continuous glucose monitor with Beta Bionics' iLet Bionic Pancreas automated insulin delivery system. This collaboration aims to combine long-term glucose sensing with adaptive insulin delivery, offering a differentiated automated insulin delivery option for people with diabetes. The integration is expected to be completed and commercially launched in the fourth quarter of 2026, pending regulatory requirements.
UBS raises Beta Bionics stock price target on FDA clearance
UBS has increased its price target for Beta Bionics (NASDAQ:BBNX) to $25.00 from $22.00, maintaining a Buy rating following FDA clearance of its Mint disposable patch pump and a new algorithm. Despite a downward revision in fiscal 2026 guidance due to customer phasing into 2027, UBS views the accelerated launch timeline as strategically positive. The company recently reported a 38% increase in Q2 2026 revenue to $32 million but posted a wider-than-expected loss per share.
FDA Clears New Type of Insulin Patch Pump From Beta Bionics
The FDA has cleared Beta Bionics Inc.'s Mint, a new type of insulin patch pump that features a reusable and disposable architecture and does not require recharging. It integrates with Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus continuous glucose monitors and with both iOS and Android smartphones. Commercial launch is expected in the first quarter of 2027 exclusively through the pharmacy channel.
Beta Bionics’ insulin patch pump gets FDA nod
Beta Bionics has received FDA clearance for its first insulin patch pump, Mint, positioning it to compete with industry leader Insulet. The company plans a full U.S. launch in Q1 2027 and expects to make the device available through the pharmacy channel. Mint is designed with both disposable and reusable components, has a three-day wear time, and a 200-unit insulin reservoir.
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm announces a class action lawsuit against Beta Bionics, Inc. (BBNX) for alleged securities fraud. Investors who purchased BBNX common stock between July 30, 2025, and February 24, 2026, are encouraged to join the lawsuit and potentially serve as lead plaintiff by November 3, 2026. The lawsuit claims Beta Bionics made misleading statements about its iLet Bionic Pancreas insulin pump, which allegedly had serious issues including malfunctioning and dangerously high insulin dosing.
